The Fox Chase Chemical Diversity Center, Inc. (FCCDC)
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant From the National Heart, Lung, and Blood Institute Entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT”
Doylestown, PA. May 17, 2014- FCCDC is pleased to announce that it has been awarded an Phase I STTR grant (R41HL123126) from the National Heart, Lung, and Blood Institute entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT” ($225,500). Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy. Heparin is a naturally-occurring anticoagulant that prevents the formation of clots within the vasculature. As a large number of hospitalized patients are exposed to heparin, HIT is a major treatment-induced cause of morbidity and mortality in this patient population. The Principal Investigator is Prof. Bruce Sachais of the University of Pennsylvania.